An Open Label, Safety Study to Assess the Potential for Adrenal Suppression and Pharmacokinetics Following Maximal Use Treatment With DSXS in Patients With Atopic Dermatitis.

Trial Profile

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression and Pharmacokinetics Following Maximal Use Treatment With DSXS in Patients With Atopic Dermatitis.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 May 2017

At a glance

  • Drugs Desoximetasone (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions
  • Sponsors Taro Pharmaceuticals USA
  • Most Recent Events

    • 16 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.
    • 16 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Aug 2017.
    • 08 Oct 2016 Planned number of patients changed from 40 to 70.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top